Advia centaur tni ultra

Troponin I (TnI) (Siemens ADVIA Centaur TnI Ultra, cut-off 40 ng/L) was collected 12 h from the onset of chest pain and used as a surrogate marker of acute myocardial injury^{32 (link)}. The invasive coronary angiography study performed during index admission was analysed using quantitative coronary arteriography analysis (QCA) by an investigator (MG) blinded to periodontal status. The Synergy between percutaneous coronary intervention with TAXUS drug-eluting stent and Cardiac Surgery Score (SYNTAX-I, http://www.syntaxscore.com/)^{33 (link)} was calculated to quantify the complexity and severity of coronary artery disease burden in native coronary vessels).

Biomarker analysis was performed before EMB. For this, a 20 mL blood sample was collected from a peripheral veinto determine the plasma levels of cardiac troponin I and BNP.
Cardiac troponin I levels were quantified with a high sensitivity 3-step sandwich immunoassay using direct chemiluminescent technology and consistent amounts of 2 monoclonal antibodies. An auxiliary reagent was included to reduce nonspecific binding using an Advia Centaur TnI-Ultra commercial kit (Siemens Healthcare Diagnostics, Tarrytown, New York, USA). The level of detection was 0.006 ng/mL (levels < 0.006 were reported as 0.005 ng/mL). The normal range of cardiac troponin I was considered < 0.04 ng/mL.
Plasma concentrations of BNP were determined with a 2-step sandwich immunoassay using direct chemiluminescent technology and consistent amounts of 2 monoclonal antibodies using an Advia Centaur commercial kit (Siemens Healthcare, Malvern, Pennsylvania, USA). The level of detection was 2 pg/mL. Levels < 2 were reported as 1 pg/mL.

Site I used a sensitive contemporary assay (ADVIA Centaur TnI-Ultra, Siemens Healthcare) [15 (link), 16 (link)]. The values of ≤0.04 ng/ml were judged as negative and values ≥0.05 ng/ml were judged as positive. For this centre, entities were defined as follows: (1) NSTEMI—initial cTn above 0.04 ng/ml, control with a rise or fall of >20 %, (2) NSTEMI—initial cTn below 0.04 ng/ml, control with a rise of >20 %, (3) high-risk (hr)-NSTE-ACS—initial cTn below 0.04 ng/ml, no further control because of prior invasive regimen and (4) hr-NSTE-ACS—initial cTn above 0.04 ng/ml, no further control because of prior invasive management.
Site II used a high-sensitivity assay (Troponin T hs, Roche Diagnostics) [17 (link), 18 (link)]. For this assay, the values of <0.014 ng/ml were judged as negative, values between 0.014 ng/ml and 0.05 ng/ml were judged as an observation zone and values >0.05 ng/ml were judged as positive. Except for the additional group (b) [NSTEMI—initial cTn within the observation zone, control with a rise or fall of >50 %], entities were defined analogue to centre I).